Home > Insider Trading > Filing (0001628280-19-014124)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1576280	Guardant Health Inc.	GH	Services-Medical Laboratories (8071)	454139254

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1753789	J Michael Wiley	505 Penobscot Drive Redwood City CA 94063	Chief Legal Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2019-10-10	40,000	$0.00	172,737	No	5	G	Direct
Common Stock	Acquisiton	2019-10-10	10,000	$0.00	10,000	No	5	G	Indirect	Isabella Wiley 2019 Irrevocable Trust
Common Stock	Acquisiton	2019-10-10	10,000	$0.00	10,000	No	5	G	Indirect	Andrew Wiley 2019 Irrevocable Trust
Common Stock	Acquisiton	2019-10-10	10,000	$0.00	10,000	No	5	G	Indirect	Coleman Wiley 2019 Irrevocable Trust
Common Stock	Acquisiton	2019-10-10	10,000	$0.00	10,000	No	5	G	Indirect	Matthew Wiley 2019 Irrevocable Trust
Common Stock	Acquisiton	2019-11-11	6,779	$4.18	179,516	No	4	M	Direct
Common Stock	Disposition	2019-11-11	2,898	$72.12	176,618	No	4	S	Direct
Common Stock	Disposition	2019-11-11	3,881	$73.08	172,737	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	5	G	Direct
No	5	G	Indirect	Isabella Wiley 2019 Irrevocable Trust
No	5	G	Indirect	Andrew Wiley 2019 Irrevocable Trust
No	5	G	Indirect	Coleman Wiley 2019 Irrevocable Trust
No	5	G	Indirect	Matthew Wiley 2019 Irrevocable Trust
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	STOCK OPTION (RIGHT TO BUY)	Disposition	2019-11-11	6,779	$0.00	6,779	$4.18

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
106,781		2027-07-13	No	4	M	Direct

Footnotes

The Reporting Person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, if any.
These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.71 to $72.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $72.72 to $73.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017.